Last reviewed · How we verify
Placebo-Repaglinide
Repaglinide is a meglitinide that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels.
Repaglinide is a meglitinide that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo-Repaglinide |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Meglitinide (rapid-acting insulin secretagogue) |
| Target | ATP-sensitive potassium channel / Sulfonylurea receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Repaglinide binds to sulfonylurea receptors on pancreatic beta cells, leading to closure of ATP-sensitive potassium channels and subsequent depolarization. This triggers calcium influx and insulin exocytosis, thereby lowering blood glucose levels. The drug has a rapid onset and short duration of action, making it suitable for mealtime glucose control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Headache
- Diarrhea
Key clinical trials
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- GLUcose Transport and REnalPROtection in Chronic Kidney Disease (PHASE2, PHASE3)
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval (PHASE1)
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib (PHASE1)
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis (NA)
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (PHASE3)
- Efficacy of Repaglinide in Subjects With Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-Repaglinide CI brief — competitive landscape report
- Placebo-Repaglinide updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI